SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2019

Notes to Financial Statements [Abstract]

Schedule of Segment Information [Table Text Block]

Segment data for the nine months ended September 30, 2019 is as follows:

		CDMO Platform			POC Platform			Corporate and Eliminations			Consolidated
		(in thousands)
Revenues from external customers	$	25,160		$	1,974		$	(2,955	)	$	24,179
Cost of revenues		(14,026	)		(1,629	)		888			(14,767	)
Segment gross profit (loss)		11,134			345			(2,067	)		9,412
Research and development expenses, net		(395	)		(5,776	)		2,092			(4,079	)
Operating expenses		(10,355	)		(5,099	)		(25	)		(15,479	)
Other income		104			—						104
Segment operating profit (loss)	$	488		$	(10,530	)	$	—		$	(10,042	)
Depreciation and amortization		(2,826	)		(17	)					(2,843	)
Segment performance	$	(2,338	)	$	(10,547	)	$			$	(12,885	)

Segment data for the nine months ended August 31, 2018 is as follows:

		CDMO Platform			POC Platform			Corporate and Eliminations			Consolidated
		(in thousands)
Revenues from external customers	$	15,807		$	83		$	(3,037	)	$	12,853
Cost of revenues		(7,826	)		—			927			(6,899	)
Segment gross profit (loss)		7,981			83			(2,110	)		5,954
Research and development expenses, net		(245	)		(4,764	)		2,110			(2,899	)
Operating expenses		(3,895	)		(4,448	)					(8,343	)
Other income		228									228
Segment operating profit (loss)	$	4,069		$	(9,129	)		—		$	(5,060	)
Depreciation and amortization		(1,807	)		(7	)					(1,814	)
Segment performance	$	2,262		$	(9,136	)				$	(6,874	)

Segment data for the three months ended September 30, 2019 is as follows:

		CDMO Platform			POC Platform			Corporate and Eliminations			Consolidated
		(in thousands)
Revenues from external customers	$	8,968		$	1,012		$	(859	)	$	9,121
Cost of revenues		(5,128	)		(728	)		(293	)		(6,149	)
Segment gross profit (loss)		3,840			284			(1,152	)		2,972
Research and development expenses, net		(101	)		(1,485	)		1,160			(426	)
Operating expenses		(3,874	)		(1,726	)		(8	)		(5,608	)
Other income		35			—						35
Segment operating loss	$	(100	)	$	(2,927	)	$	—		$	(3,027	)
Depreciation and amortization		(929	)		(7	)					(936	)
Segment performance	$	(1,029	)	$	(2,934	)	$			$	(3,963	)

Segment data for the three months ended August 31, 2018 is as follows:

		CDMO Platform			POC Platform			Corporate and Eliminations			Consolidated
		(in thousands)
Revenues from external customers	$	8,092		$	83		$	(1,945	)	$	6,230
Cost of revenues		(3,908	)		—			539			(3,369	)
Segment gross profit (loss)		4,184			83			(1,406	)		2,861
Research and development expenses, net		(245	)		(2,898	)		1,406			(1,737	)
Operating expenses		(1,712	)		(1,453	)					(3,165	)
Other income		(88	)		—						(88	)
Segment operating profit (loss)	$	2,139		$	(4,268	)				$	(2,129	)
Depreciation and amortization		(567	)		(3	)					(570	)
Segment performance	$	1,572		$	(4,271	)				$	(2,699	)

Schedule of Reconciliation of Segment Performance [Table Text Block]

Reconciliation of segment performance to loss for the nine months ended September 30, 2019:

		Nine-Months Ended September 30, 2019 (in Thousands)
Segment performance	$	(12,885	)
Stock-based compensation		(2,426	)
Stock based compensation to First    Choice		(2,641	)
Financial expenses, net		(588	)
Loss before income tax	$	(18,540	)

Reconciliation of segment performance to loss for the nine months ended August 31, 2018:

		Nine-Months Ended August 31, 2018 (in Thousands)
Segment performance	$	(6,874	)
Stock-based compensation		(2,782	)
Financial expenses, net		(3,164	)
Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date fair value		4,509
Transaction expenses related to GPP agreement		(1,500	)
Share in losses of associated company		(732	)
Loss before income tax	$	(10,543	)

Reconciliation of segment performance to loss for the three months ended September 30, 2019:

		Three-Months Ended September 30, 2019 (in Thousands)
Segment performance	$	(3,963	)
Stock-based compensation		(462	)
Financial expenses, net		(395	)
Loss before income tax	$	(4,820	)

Reconciliation of segment performance to loss for the three months ended August 31, 2018:

		Three-Months Ended August 31, 2018 (in Thousands)
Segment performance	$	(2,699	)
Stock-based compensation		(955	)
Financial expenses, net		(1,070	)
Share in losses of associated companies		(202	)
Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date fair value		4,509
Transaction expenses related to GPP agreement		(1,500	)
Loss before income tax	$	(1,917	)

Schedule of Revenues from Major Customers [Table Text Block]

	Nine Months Ended		Three Months Ended
	September 30,	August  31,	September 30,	August  31,
	2019	2018	2019	2018
	(in Thousands)
Customer A	—	2,339	—	—
Customer B	6,404	3,922	2,128	1,651
Customer C	2,651	3,109	—	956
Customer D	2,923	—	—	—
Customer E	2,876	—	990	1,100
Customer F	—	—	—	784
Customer G	2,534	—	1,518	—